Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,413 across all filing types
Latest filing 2025-12-01 Regulatory Filings
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated December 1, 2025, from Sun Pharmaceutical Industries Limited announcing the launch of a new drug, ILUMYA, in India. It contains detailed information about the drug, clinical study results, expert commentary, and background on the disease treated. The document is clearly labeled as a "Press Release" and is an announcement rather than a financial report or regulatory filing. There are no financial statements, management discussion, or regulatory compliance content. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is promotional and informational about a product launch, which aligns with a Capital/Financing Update (CAP) only if it involved financing, but here it is purely a product launch announcement. Since none of the specific categories for financial or regulatory filings apply, and it is a press release about a product launch, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing. Confidence is high because the document is clearly a press release and not a financial or governance report.
2025-12-01 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Sun Pharmaceutical Industries Limited announcing the FDA approval of a label update for their drug UNLOXCYT based on longer-term clinical data. It includes detailed clinical trial results, safety information, and background on the drug and disease. The document is regulatory in nature but is primarily a press release announcing a regulatory approval and updated labeling information, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it is the actual announcement of the label update and clinical data, not a notice about a report release. The document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about FDA approval and label update under SEBI regulations, without being a financial or governance report.
2025-11-26 English
Scheme of Arrangement
Regulatory Filings Classification · 95% confidence The document is a short communication informing the stock exchanges about the effective date of a Composite Scheme of Arrangement, referencing a regulatory compliance under SEBI Listing Obligations and Disclosure Requirements. It mentions the filing of a certified order with the Registrar of Companies and confirms compliance with directions. The document is brief (1411 characters) and serves as an official announcement rather than a detailed report or financial statement. There is no financial data, no detailed management discussion, no audit information, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership between Sun Pharmaceutical Industries Limited and AstraZeneca Pharma India Limited to promote and distribute a treatment for Hyperkalaemia in India. It is an official communication under SEBI regulations but does not contain financial statements, earnings data, management discussion, or regulatory filings. It is not an annual or quarterly report, audit report, earnings release, or any other financial or governance report. The content is a corporate announcement about a strategic partnership and product marketing collaboration. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Sun Pharmaceutical Industries Limited dated November 12, 2025. It announces the presentation of clinical study data on the drug Utreglutide (GL0034) at scientific conferences (ObesityWeek 2025 and American Heart Association 2025 Scientific Sessions). The content focuses on study results, safety, efficacy, and future plans for clinical development. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a communication of scientific and clinical data to the public and investors, typical of a press release or capital/financing update. However, it does not discuss fundraising, capital structure changes, or financing activities. It is not a full financial report or earnings release. Given the nature of the document as a press release announcing clinical data presentations, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and press releases that do not fit other categories.
2025-11-12 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Sun Pharmaceutical Industries Limited, dated 12 November 2025, providing an update on clinical study developments related to Fibromun, a drug under investigation in various Phase II and III clinical trials. The content focuses on clinical trial results, study progress, and future plans for regulatory discussions and new trials. It is not a financial report, earnings release, regulatory filing, or management discussion. The document is an announcement of clinical study updates and related information, typical of a press release. There is no indication that this is a financial or regulatory filing, nor does it contain financial statements or management analysis. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories.
2025-11-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.